Kent Malmros is senior director of training at Veeva Systems. He has spent the majority of his career delivering technology-enabled training solutions to life-sciences companies and has held ...

Pharma Insights - Thought Leadership from Marketers | Sponsored Content | Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...

David S. Thompson, CSAP, is Chief Alliance Officer at Eli Lilly and Company.

FDA approved florquinitau F 18 PET for AD evaluation in cognitively impaired adults, while excluding non-AD tauopathies because safety and effectiveness outside that population remain unestablished.

Program steering includes Eli Lilly’s Edgardo Hernandez, with C-suite perspectives on Manufacturing 5.0, digital transformation, the global generics landscape, and USP-linked supply-chain quality ...

Lee Karras CEO, Halo Pharma ties the move to US injectable capacity along with an introduction to Halo’s new sterile fill-finish platform before GMP qualification. Before GMP qualification begins, ...

Pen injector pre-assembly demands 160 PPM precision: LVDT/vision systems, tolerance control, and GAMP5 challenge testing ensure ISO 11608 compliance. The transition from traditional syringes to ...

Glenn Herring, Halo Pharma, details the CDMO's new sterile fill-finish platform, Groninger/SKAN tech, GMP/Annex 1 design, and 2026 qualification timeline.

Two AI discovery paradigms are emerging: interpretable pathway-informed gap mining versus brute-force generative enumeration, with the latter likened to stochastic search lacking validated ...

Pharma AI spending is surging, but promised gains in cycle times and attrition have not materialized, indicating a translation failure from pilots to scaled, outcome-changing deployment. Competitive ...

In this episode, we discuss AI drug discovery hype, agent security risks, and why pharma's AI workforce bets remain unproven. In the second half of a two-part deep dive on major pharma-AI partnerships ...

This week’s content included Moderna's mRNA flu approval, CMO governance tips, OSTP’s deregulation push, a $2 billion oncology license, and July's regulatory wrap-up. In the first week of August, ...